FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

56 letters match. Newest first.

  1. Signature Formulations, LLC

    FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.

    High risk
  2. HTO Nevada, Inc. dba Kirkman

    HTO Nevada dba Kirkman, an OTC drug contract manufacturer, was cited for CGMP violations including mislabeled reformulated drugs.

    High risk
  3. Fulijaya Manufacturing SDN. BHD.

    Fulijaya Manufacturing in Malaysia failed CGMP (drug manufacturing rules) for OTC drugs, with missing lab data, flawed microbial tests, and weak stability data.

    High risk
  4. Tower Laboratories Ltd.

    FDA warned Tower Laboratories, an OTC drug maker in Montague, MI, for weak out-of-specification investigations and unproven test methods.

    High risk
  5. LiquidCapsule Manufacturing, LLC

    LiquidCapsule Manufacturing failed CGMP (current good manufacturing practice) for OTC drugs, including component identity testing and process validation failures.

    High risk
  6. Private Label Skin Care, Inc.

    FDA warned Private Label Skin Care about poor quality oversight, continued sale of impurity-affected over-the-counter drugs, and missing drug listings.

    High risk